吉非替尼治疗晚期非小细胞肺癌的临床疗效及安全性  

Clinical efficacy and safety of gefitinib in the treatment of advanced non-small cell lung cancer

作　　者：张剑 ZHANG Jian(Dashiqiao Central Hospital,Dashiqiao 115100,China)

机构地区：[1]大石桥市中心医院,115100

出　　处：《中国实用医药》2022年第6期147-149,共3页China Practical Medicine

摘　　要：目的探讨吉非替尼治疗晚期非小细胞肺癌的效果和安全性。方法54例晚期非小细胞肺癌患者,以随机方法分为观察组与对照组,各27例。对照组采用厄洛替尼治疗,观察组采用吉非替尼治疗。比较两组病情控制率、不良反应发生情况。结果治疗后,观察组病情控制率92.59%高于对照组的62.96%,差异有统计学意义(P<0.05)。观察组不良反应发生率18.52%与对照组的14.81%比较,差异无统计学意义(P>0.05)。结论在对晚期非小细胞肺癌患者进行治疗时,吉非替尼的效果相对于厄洛替尼而言更好,而且具有较好的安全性,因此值得推荐。Objective To discuss the effect and safety of gefitinib in the treatment of advanced non-small cell lung cancer.Methods A total of 54 patients with advanced non-small cell lung cancer were randomly divided into observation group and control group,with 27 cases in each group.The control group was treated with erlotinib,and the observation group was treated with gefitinib.The disease control rate and the incidence of adverse reactions were compared between the two groups.Results After treatment,the disease control rate 92.59%of the observation group was higher than 62.96%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 18.52%and that in the control group was 14.81%,and the difference was not statistically significant(P>0.05).Conclusion Gefitinib is more effective than erlotinib in the treatment of patients with advanced non-small cell lung cancer,and it has better safety,so it is worth recommending.

关 键 词：吉非替尼 厄洛替尼 晚期非小细胞肺癌 效果 安全性 

分 类 号：R734.2[医药卫生—肿瘤]